The 5 most recent market catalysts affecting $SLXN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 75
Silexion Therapeutics shares are trading lower after the company reported worse-than-expected Q2 results.
The headline indicates a direct negative impact on Silexion Therapeutics (SLXN) due to its poor Q2 earnings. This is a corporate-specific catalyst, but its severity could spill ove…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 95
Silexion Therapeutics Q2 EPS $(5.17) Misses $(2.12) Estimate
Silexion Therapeutics (SLXN) announced Q2 EPS of $(5.17), missing the analyst consensus estimate of $(2.12) by a substantial 143.87%. This significant miss indicates that the compa…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 85
Silexion Therapeutics shares are trading lower after the company announced the pricing of its $2.5 million public offering of 3,846,161 shares at $0.65 per share.
The public offering by Silexion Therapeutics is a significant corporate catalyst. Pricing new shares at $0.65, likely below the prevailing market price, creates immediate dilution …
Aug 12, 2026
Corporate Catalyst
Neutral
Impact 55
Reported Earlier, Silexion Therapeutics Prices $2.5M Public Offering Of 3,846,161 Ordinary Shares At $0.65 Per Share
This public offering by Silexion Therapeutics is a moderate corporate catalyst. The primary impact is on SLXN, as the issuance of new shares at $0.65 will dilute existing sharehold…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
Silexion Therapeutics shares are trading lower after the company announced additional preclinical findings from its ongoing translational immuno-oncology program evaluating SIL204 in human KRAS-mutant cancer cells.
The headline indicates a direct negative impact on Silexion Therapeutics (SLXN) due to preclinical findings from their immuno-oncology program. While the specific details of the 'a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.